These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19341847)

  • 41. [Management of abnormal bleeding in an intrauterine device user].
    Desmons F; Adam-steen C
    Cah Sexol Clin; 1985; 11(63):185-7. PubMed ID: 12281357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.
    Chi IC
    Contraception; 1991 Dec; 44(6):573-88. PubMed ID: 1773615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of a copper intra-uterine contraceptive device on the microbial ecology of the female genital tract.
    Elhag KM; Bahar AM; Mubarak AA
    J Med Microbiol; 1988 Apr; 25(4):245-51. PubMed ID: 3357191
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Perinatal outcomes including long-term neuropsychiatric hospitalizations of offspring conceived during intrauterine contraceptive device use.
    Pariente G; Wainstock T; Sheiner E
    Contraception; 2019 Aug; 100(2):155-159. PubMed ID: 31004569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The menstrual cycle in women using an intrauterine device.
    Faundes A; Segal SJ; Adejuwon CA; Brache V; Leon P; Alvarez-Sanchez F
    Fertil Steril; 1980 Nov; 34(5):427-30. PubMed ID: 7439408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors associated with copper T IUD removal for bleeding/pain: a multivariate analysis.
    Zhang J
    Contraception; 1993 Jul; 48(1):13-21. PubMed ID: 8403901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perimenstrual dermatitis secondary to a copper-containing intrauterine contraceptive device.
    Pujol RM; Randazzo L; Miralles J; Alomar A
    Contact Dermatitis; 1998 May; 38(5):288. PubMed ID: 9667454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The intrauterine device in modern contraception: Still an actuality?
    Tinelli A; Tinelli R; Malvasi A; Cavallotti C; Tinelli FG
    Eur J Contracept Reprod Health Care; 2006 Sep; 11(3):197-201. PubMed ID: 17056450
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endometrial morphometry in users of intrauterine contraceptive devices and women with ovulatory dysfunctional uterine bleeding: a comparison with normal endometrium.
    Wang IY; Russell P; Fraser IS
    Contraception; 1995 Apr; 51(4):243-8. PubMed ID: 7796590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A three-year study of the copper-7 minigravigard intrauterine contraceptive device in nulliparous women.
    Srisupandit S
    J Med Assoc Thai; 1988 Jun; 71(6):294-7. PubMed ID: 3171448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interactions between intrauterine contraceptive device use and breast-feeding status at time of intrauterine contraceptive device insertion: analysis of TCu-380A acceptors in developing countries.
    Farr G; Rivera R
    Am J Obstet Gynecol; 1992 Jul; 167(1):144-51. PubMed ID: 1442918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review.
    Godfrey EM; Folger SG; Jeng G; Jamieson DJ; Curtis KM
    Contraception; 2013 May; 87(5):549-66. PubMed ID: 23199413
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of the reason of abnormal uterine bleeding induced by copper corrosion of IUD Cu.
    Li L; Li J; Li N; Zhang Y; Feng X
    Clin Exp Obstet Gynecol; 2016; 43(6):883-886. PubMed ID: 29944244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
    Singata-Madliki M; Lawrie TA; Balakrishna Y; d'Hellencourt FC; Hofmeyr GJ
    Reprod Health; 2021 Sep; 18(1):192. PubMed ID: 34587971
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study.
    Barnett C; Moehner S; Do Minh T; Heinemann K
    Eur J Contracept Reprod Health Care; 2017 Dec; 22(6):424-428. PubMed ID: 29322856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparative study of the effect of the Progestasert TM and Gravigard IUDs on dysmenorrhoea.
    Pizarro E; Gomez-Rogers C; Rowe PJ
    Contraception; 1979 Nov; 20(5):455-66. PubMed ID: 527341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Reasons for removal of intrauterine devices among women in general practice].
    Kolding L; Majeed HG
    Ugeskr Laeger; 2013 Mar; 175(13):884-6. PubMed ID: 23582897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bleeding, cramping, and satisfaction among new copper IUD users: A prospective study.
    Sanders JN; Adkins DE; Kaur S; Storck K; Gawron LM; Turok DK
    PLoS One; 2018; 13(11):e0199724. PubMed ID: 30403671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for copper T IUD expulsion: an epidemiologic analysis.
    Zhang J; Feldblum PJ; Chi IC; Farr MG
    Contraception; 1992 Nov; 46(5):427-33. PubMed ID: 1458889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.